8-K: BioAffinity Reports Q3 2025 Results, CyPath Lung Revenue Soars 122%

BioAffinity Technologies reported a 122% year-over-year increase in CyPath Lung testing revenue for Q3 2025, alongside a strategic shift from unprofitable pathology services.

Summary

• Total revenue for the three months ended September 30, 2025, was $1.5 million, a decrease from $2.4 million in the same period of 2024, primarily due to the strategic discontinuation of unprofitable pathology services.
• CyPath Lung testing revenue increased by approximately 122% year-over-year in Q3 2025, driven by growing physician adoption and increased test volumes.
• For the first nine months of 2025, CyPath Lung revenues increased 86% year-over-year, and the number of tests processed increased by 97% over the same period in 2024.
• The company successfully raised approximately $10.4 million in gross proceeds from equity transactions in Q3 2025 to fund ongoing operations and growth initiatives.
• Net loss for Q3 2025 was $5.1 million, or $4.74 per share, compared to a net loss of $2.0 million, or $4.84 per share, in Q3 2024, primarily due to a $2.7 million expense for the change in fair value of warrants issued.
• Cash and cash equivalents significantly increased to $7.7 million as of September 30, 2025, from $1.1 million as of December 31, 2024.
• Operating expenses decreased by 16% year-over-year to $3.7 million in Q3 2025, reflecting cost-saving initiatives and streamlining of laboratory operations.
• The company regained full Nasdaq Capital Market compliance for the continued listing of its common stock and warrants.
• Two new directors, Roberto Rios, CPA, and John J. Oppenheimer, M.D., were appointed to the Board of Directors.
• A new U.S. patent was granted, protecting the diagnostic algorithm and test method used in CyPath Lung.

Sentiment

Score: 6

Explanation: While total revenue decreased and net loss widened due to a non-cash warrant valuation adjustment, the significant growth in CyPath Lung revenue (122% YOY), successful capital raise, cost-saving initiatives, and regaining Nasdaq compliance are strong positive indicators for the company's strategic direction and financial stability. The increased net loss is primarily due to a non-cash item, and the core business (CyPath Lung) shows strong momentum.

Positives

• CyPath Lung testing revenue increased by approximately 122% year-over-year in Q3 2025.
• CyPath Lung sales reached a record high in Q3 2025, representing a 92% increase over the previous quarter.
• For the first nine months of 2025, CyPath Lung revenues increased 86% year-over-year.
• The number of CyPath Lung tests processed increased by 97% in the first nine months of 2025 over the same period in 2024.
• Successfully raised approximately $10.4 million in gross proceeds from equity transactions, significantly strengthening the balance sheet with cash and cash equivalents rising to $7.7 million as of September 30, 2025.
• Operating expenses decreased by 16% year-over-year to $3.7 million in Q3 2025 due to cost-saving initiatives.
• Regained full Nasdaq Capital Market compliance for continued listing of common stock and warrants.
• Expanded patent portfolio with a new U.S. patent protecting the CyPath Lung diagnostic algorithm and test method.
• Appointment of two experienced directors, Roberto Rios (corporate finance) and John J. Oppenheimer (lung health diagnosis/treatment), to the Board.
• Positive patient case studies demonstrating CyPath Lung's ability to detect Stage 1A lung cancer and spare unnecessary biopsies.
• Growing adoption by VA hospitals and market expansion in the mid-Atlantic region.

Negatives

• Total revenues decreased from $2.4 million in Q3 2024 to $1.5 million in Q3 2025, a 37.5% decline, due to the strategic decision to discontinue unprofitable pathology services.
• Net loss for Q3 2025 significantly increased to $5.1 million, compared to $2.0 million in Q3 2024, primarily driven by a $2.7 million expense for the change in fair value of warrants issued.
• Research and development expenses increased 20% year-over-year to $330,000 in Q3 2025.
• Clinical development expenses increased 52% year-over-year to $143,000 in Q3 2025.
• The Nasdaq compliance is subject to a mandatory panel monitor for a period of one year.

Risks

• Clinical adoption of CyPath Lung may not meet expectations.
• Strategic actions to reduce costs and expand sales focus on high-margin diagnostics may not yield desired results.
• International patents may not effectively expand CyPath Lung's global commercialization potential.
• Targeted actions may not accelerate the commercial growth of CyPath Lung as anticipated.
• Patient case studies may not continue to underscore the diagnostic power of CyPath Lung in real-world settings.
• Efforts to expand access to CyPath Lung for patients at risk of lung cancer may face challenges.
• Advancing new diagnostics for diseases like COPD and asthma may encounter development or commercialization hurdles.
• General risks discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.

Future Outlook

The company anticipates continued clinical adoption and commercial growth of CyPath Lung, driven by strategic actions to reduce costs and focus on high-margin diagnostics. They expect patient case studies to further highlight the diagnostic power of CyPath Lung and aim to expand access for at-risk patients. Additionally, the company plans to advance new diagnostics for diseases such as COPD and asthma, leveraging its expanded intellectual property portfolio.

Management Comments

• "In the third quarter of 2025, our primary focus was on driving the adoption of CyPath Lung while maintaining fiscal discipline."
• "The strong increase in CyPath Lung testing revenue reflects growing confidence among physicians who are recognizing our tests ability to detect early-stage lung cancer when it is most treatable."
• "The continued publication of case studies in which patients have benefited from Stage 1A lung cancer detection and others have been spared unnecessary and costly biopsies is particularly impactful."
• "Our marketing program to the VA is showing results in terms of both sales and interest in participating in our upcoming longitudinal study."
• "Now VA clinicians have access to a powerful tool to detect lung cancer early when treatment can save lives."
• "We raised approximately $10.4 million in gross proceeds from equity transactions in the third quarter to fund ongoing operations."
• "We are also seeing the results of our targeted strategic actions announced in March to streamline laboratory operations and reduce costs by discontinuing certain unprofitable pathology services at our wholly owned laboratory. This has allowed us to focus additional resources on our flagship diagnostic, CyPath Lung."
• "We expanded our intellectual property portfolio for the second quarter in a row with an important U.S. patent that protects our proprietary algorithm which results in CyPath Lungs superior test performance of 92% sensitivity and 87% specificity for patients with small pulmonary nodules."
• "Mr. Rios business and financial expertise combined with Dr. Oppenheimers clinical and strategic leadership will be invaluable as we increase sales of CyPath Lung, develop companion diagnostics for asthma and COPD, and continue to build shareholder value."

Industry Context

This announcement highlights the growing trend in the biotechnology and diagnostics industry towards non-invasive, early-stage disease detection, particularly for cancers like lung cancer where early diagnosis significantly improves patient outcomes. The focus on AI and flow cytometry in CyPath Lung aligns with the broader industry shift towards advanced diagnostic technologies. The company's engagement with the Veterans Administration also reflects a strategic move to address high-risk populations and secure government contracts, a common strategy for medical device and diagnostic companies. The discontinuation of unprofitable pathology services indicates a strategic pivot towards higher-margin, proprietary diagnostic products, a common move for companies seeking to optimize their business model in competitive markets.

Comparison to Industry Standards

• CyPath Lung's reported performance of 92% sensitivity and 87% specificity for detecting lung cancer in high-risk patients with small lung nodules (less than 20 millimeters) positions it favorably against other non-invasive lung cancer screening methods. For example, low-dose computed tomography (LDCT) is the current standard for high-risk individuals, but it often leads to a high rate of false positives, necessitating follow-up invasive procedures.
• The emphasis on detecting Stage 1A lung cancer and avoiding unnecessary biopsies suggests a competitive advantage in reducing the burden and cost associated with false positives from other screening methods.
• The company's strategic focus on the Veterans Administration (VA) market is a significant move, as the VA serves a large population at higher risk for lung cancer, providing a substantial target market for CyPath Lung. This strategy is comparable to other medical technology companies that target specific large healthcare systems or government programs for market penetration.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from strengthened balance sheet ($10.4M capital raise), regained Nasdaq compliance, and strong growth in the core product (CyPath Lung). However, dilution from equity transactions and increased net loss (though largely non-cash) could be concerns.
• Employees: Strategic actions to streamline laboratory operations and discontinue unprofitable services may have led to some operational changes, but the focus on CyPath Lung suggests a clear direction for the core team.
• Customers (Physicians/VA): Increased confidence in CyPath Lung due to strong performance data and case studies, leading to growing adoption. VA clinicians gain access to a powerful early detection tool.
• Patients: Benefit from early-stage lung cancer detection (Stage 1A) and avoidance of unnecessary, costly biopsies due to CyPath Lung's accuracy.
• Creditors: Improved financial position with increased cash and reduced total liabilities.

Next Steps

• Continue driving adoption of CyPath Lung.
• Participate in an upcoming longitudinal study with the Veterans Administration.
• Increase sales of CyPath Lung.
• Develop companion diagnostics for asthma and COPD.
• Continue to build shareholder value.
• Monitor Nasdaq compliance for one year.

Key Dates

Recommendation

While the company shows strong growth in its core diagnostic product, CyPath Lung, and has significantly improved its cash position through a capital raise, the overall revenue decline and increased net loss (even if partially due to non-cash items) present a mixed financial picture. The strategic shift is positive, but the company is still in a growth phase with ongoing R&D and clinical development expenses. The Nasdaq compliance is a positive, but the one-year monitor indicates continued scrutiny. A 'hold' recommendation allows investors to observe the sustained commercialization success of CyPath Lung and the impact of new board members and strategic initiatives on the company's profitability and market expansion before making a stronger commitment.

Keywords

Lung cancer detection, Noninvasive diagnostic, CyPath Lung, Biotechnology, Early-stage cancer, SEC filing, Financial results, Q3 2025, BioAffinity Technologies, BIAF, Sputum test, AI diagnostics, Flow cytometry, Veterans Administration, Corporate governance, Patent, Capital raise